Skip to main navigation Skip to search Skip to main content

Improvement in subjective and objective neurocognitive functions in patients with major depressive disorder: A 12-week, multicenter, randomized trial of tianeptine versus escitalopram, the CAMPION study

  • Hong Jin Jeon
  • , Jong Min Woo
  • , Seung Hwan Lee
  • , Eui Joong Kim
  • , Seockhoon Chung
  • , Jee Hyun Ha
  • , Maurizio Fava
  • , David Mischoulon
  • , Ji Hae Kim
  • , Jung Yoon Heo
  • , Bum Hee Yu
  • Inje University
  • Eulji University
  • University of Ulsan
  • Konkuk University
  • Massachusetts General Hospital
  • Sungkyunkwan University

Research output: Contribution to journalArticlepeer-review

Abstract

Although many patients with major depressive disorder (MDD) complain of neurocognitive impairment, the effects of antidepressant medications on neurocognitive functions remain unclear. This study compares neurocognitive effects of tianeptine and escitalopram in MDD. Patients with MDD (N = 164) were randomly assigned in a 1:1 ratio to either tianeptine (37.5 mg/d) or escitalopram (10 mg/d) for 12 weeks. Outcome measures included clinical improvement, subjective cognitive impairment on memory and concentration, the Mini-Mental State Examination, the Continuous Performance Test, the Verbal Learning Test, and the Raven Progressive Matrices, assessed every 4 weeks. After 12 weeks, the tianeptine group showed significant improvement in commission errors (P = 0.002), verbal immediate memory (P < 0.0001), Mini-Mental State Examination (P < 0.0001), delayed memory (P < 0.0001), and reasoning ability (P = 0.0010), whereas the escitalopram group improved in delayed memory and reasoning ability but not in the other measures. Both groups significantly improved in subjective cognitive impairment in memory (P < 0.0001) and concentration (P < 0.0001). Mixed effects model repeated measures analyses revealed that the tianeptine group had a significant improvement in scores of commission errors (F = 6.64, P = 0.011) and verbal immediate memory (F = 4.39, P = 0.038) from baseline to 12 weeks, compared with the escitalopram group, after controlling for age, sex, education years, baseline scores, and changes of depression severity. The treatment of MDD with tianeptine led to more improvements in neurocognitive functions, especially in commission errors and verbal immediate memory, compared with escitalopram, after controlling for changes in depression severity. Both drugs improved subjective cognitive impairment of memory and concentration.

Original languageEnglish
Pages (from-to)218-225
Number of pages8
JournalJournal of Clinical Psychopharmacology
Volume34
Issue number2
DOIs
StatePublished - Apr 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being
  2. SDG 5 - Gender Equality
    SDG 5 Gender Equality

Keywords

  • Escitalopram
  • Major depressive disorder
  • Neurocognitive
  • Tianeptine

Fingerprint

Dive into the research topics of 'Improvement in subjective and objective neurocognitive functions in patients with major depressive disorder: A 12-week, multicenter, randomized trial of tianeptine versus escitalopram, the CAMPION study'. Together they form a unique fingerprint.

Cite this